Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity

Abstract

Subcutaneous human parathyroid hormone (hPTH) therapy can effectively manage hypocalcemia in hypoparathyroidism, with varying effects on hypercalciuria. However, little is known about its ability to decrease the renal comorbidities of hypoparathyroidism: nephrocalcinosis (NC), nephrolithiasis (NL), and renal insufficiency. Urinary citrate (Ucit) promotes the solubility of urinary calcium (UCa); hypocitraturia is a risk factor for NC/NL. Twenty-four-hour UCa, Ucit, and UCa/Ucit were determined in 31 hypoparathyroid subjects receiving hPTH 1-34 therapy for up to 5 years. Before hPTH 1-34, the geometric least squares mean UCa was 346 mg/day (normal <250) and Ucit was 500 mg/day (normal 250-1190); UCa/Ucit was 0.67 mg/mg. After 6 months of hPTH 1-34, UCa decreased (238, p < 0.001), but with a greater decrease in Ucit (268, p < 0.001), increasing UCa/Ucit, which became significant over time (p < 0.001). After stopping hPTH 1-34 and resuming conventional therapy (follow-up; FU), compared to the last measures on hPTH 1-34, Ucit rose to 626 (p < 0.001), reducing UCa/Ucit to 0.44, (p < 0.05); UCa also rose (273), but was still lower than baseline (p < 0.05). Daily hPTH 1-34 dose did not correlate with UCa, but was inversely related to Ucit, and directly related to UCa/Ucit (p < 0.01). Mean blood bicarbonate decreased significantly on hPTH 1-34 and remained lower than baseline at FU (p < 0.01). Mean eGFR increased on hPTH 1-34 (86 to 96 mL/min/1.73 m , p < 0.001) and returned to baseline at FU. On renal imaging, 6 subjects did not have NC/NL, 8 had NC/NL prior to hPTH 1-34 that remained unchanged, and 16 developed new-onset (n = 10) or progressive (n = 6) NC/NL while on hPTH 1-34. Our data demonstrate that treatment with subcutaneous hPTH 1-34 may have an untoward effect of hypocitraturia and high UCa/Ucit ratio that may increase renal morbidity. With increasing use of PTH therapy in hypoparathyroidism, close monitoring and exploration for treatment of hypocitraturia seem warranted. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis

“…A recent paper by Gafni and coworkers 57 seems to suggest that treatment with subcutaneous PTH 1-34 in patients with hypoparathyroidism may have untoward effects of hypocitraturia, thus increasing renal morbidity. No similar study has been carried out in the setting of osteoporosis; however, this possible biochemical abnormality should be better defined in patients receiving the hormone not as a substitution therapy.…”

PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism

“…This was a longitudinal open‐label, uncontrolled study of synthetic human PTH 1‐34 (hPTH) replacement therapy in 31 patients with hypoparathyroidism (25 women, six men), ages 16 to 60 years old. ( 27 ) Included patients had physician‐diagnosed hypoparathyroidism for at least 1 year, confirmed by an intact PTH <30 pg/mL with concomitant blood calcium below the normal range upon screening. The majority of patients ( 20 ) had postsurgical hypoparathyroidism; four had activating pathogenic variants of the calcium‐sensing receptor, two had 22q11.2 deletion syndrome, one had hypoparathyroidism‐deafness‐renal syndrome, and four had idiopathic/acquired autoimmune disease.…”

Tissue‐engineered parathyroid gland and its regulatory secretion of parathyroid hormone

“…Winer et al showed that twice daily PTH (1‐34) kept a more stable metabolic level than the once‐daily dose (Winer, Sinaii, Peterson, Sainz, & Cutler, 2008). Overdosed PTH (1‐34) has the potential to bring hypocitraturia that is harmful to kidneys (Gafni et al, 2018). As for transplantation, allotransplantation was first used in postsurgical hypoparathyroidism but is still not popular enough considering the shortage of safe and functional cell or tissue resources (Agha et al, 2016; Khryshchanovich & Ghoussein, 2016; Tibell et al, 2001).…”